Search 

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

ASTEC is a Tokyo-based, accelerator-type investment firm focused on company creation and seed-stage investment. We have been solely investing in Japan but now plans to launch a new fund, together with Tokyo-based FinTech Global Capital, that also invests in other geography leveraging our Japan connection, both academic inventions and pharmaceutical companies. ASTEC deeply gets involved with the management of its portfolio companies and represents some of them for BD activities.

Arizona’s bioscience and health care industry benefits from strong relationships with major institutions, hospitals, private firms and the state's public universities. CNBC ranks the state second nationwide in availability of skilled workforce, and biomedical jobs are growing three times faster than the national average.  In addition to our aggressive incentive programs, Arizona is committed to attracting and supporting quality companies through competitive tax policies and has demonstrated a continued trend of reducing property, individual sales and corporate income tax rates.  An example of some of the key programs and incentives for the biosciences includes:

• AZ Innovation Challenge – $3 million ($1.5 million twice yearly) for technology commercialization to the world’s most promising technology ventures. Awards range from $100,000 to $250,000 per company.

• Angel Investment Tax Credit - provides tax credits up to 35% for investors who make capital investment in small businesses certified by the Arizona Commerce Authority (ACA).   

• Arizona Innovation Accelerator Fund - an $18.2 million loan participation program to stimulate financing of small businesses and manufacturers by providing debt financing up to $2 million.  Recognized by the US Treasury as a Best Practice model of its kind

• R&D Tax Credit/Refund – refundable and non-refundable programs for increased R&D activities.  Income tax credits up to 34% for qualified expenses. Up to 75% of the excess tax credit can be refunded.

Boehringer Ingelheim was founded in 1885 and is based in Ingelheim am Rhein Germany. The firm invests by means of in-licensing and acquisitions and is primarily focused on respiratory diseases cardiovascular diseases metabolic diseases oncology diseases of the central nervous system and immunology. Boehringer Ingelheim also invests in veterinary medicine.

Chempetitive Group is an integrated marketing communications agency focused exclusively on the life sciences. We work with biotech, medical device, pharmaceutical, chemical and tools/instrumentation companies of all sizes that around the globe. We develop winning strategies and campaigns that build brands and generate revenues. We love science. We understand science. And, we know how to effectively reach the scientific, clinical, medical and business communities that matter. 

Long live science. 

Visit us in San Diego, San Francisco, Chicago, Boston or Cambridge UK. 

Find out about us at http://www.chempetitive.com 

Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies. 

Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.

DavosPharma’s corporate offering covers all the activities required to get a drug from conception to commercialization. DavosPharma has been filling this need since 1972, serving the pharmaceutical and life science market by providing discovery chemistry & biology, pre-clinical development, and all required CMC activities including custom synthesis of organic molecules, custom dosage formulation, and custom manufacturing of cGMP intermediates, APIs, and drug product.